| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$178,118 ) |
| | 2025 | 2022 | SITEONE THERAPEUTICS, INC. | 280 UTAH AVE STE 250 | SOUTH SAN FRANCISCO | CA | 94080-6819 | SAN MATEO | USA | R44EY033267 | Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain | 000 | 2 | NIH | 4/28/2025 | -$178,118 |
|
| Issue Date FY: 2024 ( Subtotal = -$538,457 ) |
| | 2024 | 2023 | SITEONE THERAPEUTICS, INC. | 280 UTAH AVE | SOUTH SAN FRANCISCO | CA | 94080-6819 | SAN MATEO | USA | UG3DA058552 | Development of a Potent and Selective Nav1.8 inhibitor for the Treatment of Acute and Chronic Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders | 000 | 1 | NIH | 10/13/2023 | $0 |
| | 2024 | 2023 | SITEONE THERAPEUTICS, INC. | 280 UTAH AVE STE 250 | SOUTH SAN FRANCISCO | CA | 94080-6819 | SAN MATEO | USA | UG3DA058552 | Development of a Potent and Selective Nav1.8 inhibitor for the Treatment of Acute and Chronic Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders | 001 | 1 | NIH | 8/5/2024 | $0 |
| | 2024 | 2022 | SITEONE THERAPEUTICS, INC. | 280 UTAH AVE STE 250 | SOUTH SAN FRANCISCO | CA | 94080-6819 | SAN MATEO | USA | R44HL147776 | Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough | 000 | 3 | NIH | 9/12/2024 | -$528,789 |
| | 2024 | 2020 | SITEONE THERAPEUTICS, INC. | 280 UTAH AVE STE 250 | SOUTH SAN FRANCISCO | CA | 94080-6819 | SAN MATEO | USA | UG3DA049599 | Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders | 000 | 2 | NIH | 11/20/2023 | -$9,668 |
|
| Issue Date FY: 2023 ( Subtotal = $5,339,405 ) |
| | 2023 | 2023 | SITEONE THERAPEUTICS, INC. | 280 UTAH AVE | SOUTH SAN FRANCISCO | CA | 94080-6819 | SAN MATEO | USA | UG3DA058552 | Development of a Potent and Selective Nav1.8 inhibitor for the Treatment of Acute and Chronic Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders | 000 | 1 | NIH | 5/4/2023 | $5,341,667 |
| | 2023 | 2021 | SITEONE THERAPEUTICS, INC. | 280 UTAH AVE STE 250 | SOUTH SAN FRANCISCO | CA | 94080-6819 | SAN MATEO | USA | U44NS111779 | Discovery of NaV1.7 Inhibitors for the Treatment of Pain | 000 | 3 | NIH | 10/17/2022 | -$2,262 |
|
| Issue Date FY: 2022 ( Subtotal = $1,615,788 ) |
| | 2022 | 2022 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44EY033267 | Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain | 001 | 2 | NIH | 9/1/2022 | $559,962 |
| | 2022 | 2022 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44HL147776 | Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough | 001 | 3 | NIH | 4/30/2022 | $1,055,826 |
| | 2022 | 2021 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44EY033267 | Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain | 000 | 1 | NIH | 10/22/2021 | $0 |
| | 2022 | 2021 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | U44NS111779 | Discovery of NaV1.7 Inhibitors for the Treatment of Pain | 002 | 3 | NIH | 7/28/2022 | $0 |
| | 2022 | 2021 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | U44NS111779 | Discovery of NaV1.7 Inhibitors for the Treatment of Pain | 001 | 3 | NIH | 5/5/2022 | $0 |
| | 2022 | 2021 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44HL147776 | Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough | 000 | 2 | NIH | 3/14/2022 | $0 |
| | 2022 | 2020 | SITEONE THERAPEUTICS, INC. | 280 UTAH AVE | SOUTH SAN FRANCISCO | CA | 94080-6819 | SAN MATEO | USA | U44NS111779 | Discovery of NaV1.7 Inhibitors for the Treatment of Pain | 000 | 2 | NIH | 10/16/2021 | $0 |
| | 2022 | 2020 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | UG3DA049599 | Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders | 000 | 2 | NIH | 8/29/2022 | $0 |
| | 2022 | 2019 | SITEONE THERAPEUTICS, INC. | 280 UTAH AVE | SOUTH SAN FRANCISCO | CA | 94080-6819 | SAN MATEO | USA | R44EY025921 | GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN | 000 | 3 | NIH | 10/13/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,214,305 ) |
| | 2021 | 2021 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44EY033267 | Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain | 000 | 1 | NIH | 8/27/2021 | $1,081,115 |
| | 2021 | 2021 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | U44NS111779 | Discovery of NaV1.7 Inhibitors for the Treatment of Pain | 000 | 3 | NIH | 5/15/2021 | $455,622 |
| | 2021 | 2021 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44HL147776 | Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough | 000 | 2 | NIH | 5/7/2021 | $677,568 |
| | 2021 | 2020 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | UG3DA049599 | Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders | 000 | 2 | NIH | 2/26/2021 | $0 |
| | 2021 | 2019 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R43HL147776 | Development of NaV1.7 Inhibitors for the Treatment of Chronic Cough | 000 | 1 | NIH | 8/26/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,902,009 ) |
| | 2020 | 2020 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | U44NS111779 | Discovery of NaV1.7 Inhibitors for the Treatment of Pain | 001 | 2 | NIH | 4/17/2020 | $461,907 |
| | 2020 | 2020 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | UG3DA049599 | Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders | 001 | 2 | NIH | 8/18/2020 | $2,440,102 |
| | 2020 | 2019 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | UG3DA049599 | Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders | 000 | 1 | NIH | 11/7/2019 | $0 |
| | 2020 | 2019 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | U44NS111779 | Discovery of NaV1.7 Inhibitors for the Treatment of Pain | 000 | 1 | NIH | 3/18/2020 | $0 |
| | 2020 | 2019 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R43HL147776 | Development of NaV1.7 Inhibitors for the Treatment of Chronic Cough | 000 | 1 | NIH | 8/25/2020 | $0 |
| | 2020 | 2019 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44EY025921 | GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN | 000 | 3 | NIH | 3/12/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $4,376,764 ) |
| | 2019 | 2019 | SITEONE THERAPEUTICS, INC. | 203 ENTERPRISE BLVD STE 3 | BOZEMAN | MT | 59718-5977 | GALLATIN | USA | R43HL147776 | Development of NaV1.7 Inhibitors for the Treatment of Chronic Cough | 001 | 1 | NIH | 4/30/2019 | $106,497 |
| | 2019 | 2019 | SITEONE THERAPEUTICS, INC. | 203 ENTERPRISE BLVD STE 3 | BOZEMAN | MT | 59718-5977 | GALLATIN | USA | R44EY025921 | GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN | 001 | 3 | NIH | 8/13/2019 | $888,892 |
| | 2019 | 2019 | SITEONE THERAPEUTICS, INC. | 203 ENTERPRISE BLVD STE 3 | BOZEMAN | MT | 59718-5977 | GALLATIN | USA | U44NS111779 | Discovery of NaV1.7 Inhibitors for the Treatment of Pain | 000 | 1 | NIH | 5/1/2019 | $226,176 |
| | 2019 | 2019 | SITEONE THERAPEUTICS, INC. | 203 ENTERPRISE BLVD STE 3 | BOZEMAN | MT | 59718-5977 | GALLATIN | USA | UG3DA049599 | Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders | 000 | 1 | NIH | 9/25/2019 | $2,937,963 |
| | 2019 | 2019 | SITEONE THERAPEUTICS, INC. | 203 ENTERPRISE BLVD STE 3 | BOZEMAN | MT | 59718-5977 | GALLATIN | USA | R43HL147776 | Development of NaV1.7 Inhibitors for the Treatment of Chronic Cough | 000 | 1 | NIH | 4/26/2019 | $217,236 |
| | 2019 | 2018 | SITEONE THERAPEUTICS, INC. | 203 ENTERPRISE BLVD STE 3 | BOZEMAN | MT | 59718-5977 | GALLATIN | USA | R44EY025921 | GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN | 000 | 2 | NIH | 11/30/2018 | $0 |
| | 2019 | 2017 | SITEONE THERAPEUTICS, INC. | 351 EVERGREEN DR STE B-1 | BOZEMAN | MT | 59715-2438 | GALLATIN | USA | R44NS081887 | Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain | 001 | 5 | NIH | 8/13/2019 | $0 |
| | 2019 | 2017 | SITEONE THERAPEUTICS, INC. | 203 ENTERPRISE BLVD STE 3 | BOZEMAN | MT | 59718-5977 | GALLATIN | USA | R44NS081887 | Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain | 000 | 5 | NIH | 3/11/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $601,128 ) |
| | 2018 | 2018 | SITEONE THERAPEUTICS, INC. | 203 ENTERPRISE BLVD STE 3 | BOZEMAN | MT | 59718-5977 | GALLATIN | USA | R44EY025921 | GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN | 000 | 2 | NIH | 9/20/2018 | $601,128 |
| | 2018 | 2015 | SITEONE THERAPEUTICS, INC. | 203 ENTERPRISE BLVD STE 3 | BOZEMAN | MT | 59718-5977 | GALLATIN | USA | R43EY025921 | Guanidinium Derivatives for the Treatment of Ocular Pain | 000 | 1 | NIH | 2/26/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $829,314 ) |
| | 2017 | 2017 | SITEONE THERAPEUTICS, INC. | 203 ENTERPRISE BLVD STE 3 | BOZEMAN | MT | 59718-5977 | GALLATIN | USA | R44NS081887 | Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain | 001 | 5 | NIH | 8/18/2017 | $829,314 |
| | 2017 | 2015 | SITEONE THERAPEUTICS, INC. | 203 ENTERPRISE BLVD STE 3 | BOZEMAN | MT | 59718-5977 | GALLATIN | USA | R44NS081887 | Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain | 000 | 3 | NIH | 8/16/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $616,855 ) |
| | 2016 | 2016 | SITEONE THERAPEUTICS INC | 600 CASTLE HILL ROAD | REDWOOD CITY | CA | 94061 | SAN MATEO | USA | R44NS081887 | Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain | 000 | 4 | NIH | 7/19/2016 | $616,855 |
|
|
